Fulcrum Therapeutics
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Fulcrum Therapeutics generated cash of -$90,965,000, which is more than the previous year. Cash used in financing activities reached the amount of $118,122,000 last year. Net change in cash is therefore -$9,535,000.
Cash Flow
| 2017 | -20.07M | -1.90M | 17.66M |
|---|---|---|---|
| 2018 | -22.56M | -8.98M | 105.02M |
| 2019 | -39.48M | -944K | 64.34M |
| 2020 | -53.65M | -57.13M | 71.13M |
| 2021 | -78.47M | -129.66M | 186.50M |
| 2022 | -97.05M | 12.41M | 84.32M |
| 2023 | -90.96M | -36.69M | 118.12M |
FULC Cash Flow Statement (2017 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|
Cash at beginning of period | 36.19M | 36.50M | 58.14M | 97.80M | 73.88M | 407K | 4.72M |
Operating activities | |||||||
Net income | -97.33M | -109.87M | -80.84M | -70.81M | -82.67M | -32.58M | -22.96M |
| Adjustments to reconcile net income to cash generated by operating activities: | |||||||
Depreciation and amortization | 2.17M | 2.41M | 2.51M | 2.37M | 2.05M | 1.34M | 715K |
Stock-based compensation expense | 14.80M | 13.35M | 11.07M | 7.35M | 4.22M | 0 | 1.37M |
| Deferred income tax benefit | 14.80M | 13.35M | 11.07M | 7.35M | 4.22M | 0 | 1.37M |
| Changes in operating assets and liabilities: | |||||||
Accounts receivable, net | -308K | 2.5M | -500K | -2M | 0 | 0 | 0 |
Inventories | 0 | 0 | 1.24M | 229K | 0 | 0 | 0 |
Accounts payable | -853K | -1.17M | 973K | 1.77M | 803K | -20K | 208K |
Cash generated by operating activities | -90.96M | -97.05M | -78.47M | -53.65M | -39.48M | -22.56M | -20.07M |
Investing activities | |||||||
Purchases Of Investments | -194.89M | -151.15M | -216.23M | -124.27M | 0 | 0 | 0 |
Investments In Property Plant And Equipment | -508K | -1.96M | -1.71M | -1.34M | -853K | -8.98M | -1.90M |
Acquisitions Net | 0 | -14.37M | 127.95M | 55.79M | 0 | 0 | 0 |
Cash generated by investing activities | -36.69M | 12.41M | -129.66M | -57.13M | -944K | -8.98M | -1.90M |
Financing activities | |||||||
Common Stock Issued | 117.34M | 80.80M | 182.85M | 69.94M | 64.17M | 12K | 41K |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | -193K | 0 | 0 | 0 |
Repayments of term debt | 0 | 0 | -18K | -50K | -45K | -70K | 0 |
Cash used in financing activities | 118.12M | 84.32M | 186.50M | 71.13M | 64.34M | 105.02M | 17.66M |
Net Change In Cash | -9.53M | -314K | -21.64M | -39.66M | 23.91M | 73.48M | -4.32M |
Cash at end of period | 26.65M | 36.19M | 36.50M | 58.14M | 97.80M | 73.88M | 407K |
| Data source | Data source | Data source | Data source | Data source |